Search consultations


Proposal To Fund An Additional Brand Of Budesonide With Eformoterol Dry Powder Inhaler

NZNO warmly invites your feedback on PHARMAC’s proposal to fund an additional brand (DuoResp Spiromax) of two of the three funded strengths of budesonide with eformoterol dry powder inhaler from 1 October 2020 through a provisional agreement with Teva Pharmaceuticals Ltd ("Teva").

Further information can be seen here.

Please note the short consultation timeframe.

If the Policy Team receives no feedback, NZNO will not make a submission.

Please send feedback to by 10 August 2020.

Notify me when this page changes

Enter your email address below to receive alerts when this page is updated.

Sign up below to receive an email when we update this page

Enter the code shown above in the box below.